Thomas Steyer’s Centessa Pharmaceuticals CNTA Stock Holding History

Thomas Steyer’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,809,000	Closed	-$191M	–	111
2026 Q1	$191M	Sell	4,809,000 -568,068	-11%	-$14.5M	1%	32
2025 Q4	$134M	Buy	5,377,068 +1,045,750	+24%	+$26.5M	0.58%	42
2025 Q3	$105M	Sell	4,331,318 -198,000	-4%	-$3.52M	0.43%	44
2025 Q2	$59.5M	Buy	4,529,318 +195,000	+4%	+$2.47M	0.25%	52
2025 Q1	$62.3M	Buy	4,334,318 +835,609	+24%	+$13.7M	0.3%	53
2024 Q4	$58.6M	Buy	3,498,709 +684,391	+24%	+$11.3M	0.26%	56
2024 Q3	$45M	Buy	2,814,318 +818,318	+41%	+$10M	0.2%	68
2024 Q2	$18M	Buy	1,996,000 +1,625,000	+438%	+$15.4M	0.08%	77
2024 Q1	$4.19M	Buy	+371,000	New	+$3.51M	0.02%	105

Thomas Steyer's CNTA Position: Q2 2026 in Review

Thomas Steyer sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 4,809,000 shares — an estimated $191M sold.

Thomas Steyer first reported a position in CNTA in Q1 2024 and held it in 9 quarters. The position peaked at $191M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Thomas Steyer reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Thomas Steyer sold 4,809,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $191M.
Thomas Steyer first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 9 quarters.
Thomas Steyer's Centessa Pharmaceuticals position peaked at $191M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.